Apr 09, 2026 7:05am EDT Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Mar 30, 2026 7:05am EDT Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update
Feb 04, 2026 7:05am EST Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit
Jan 29, 2026 9:15am EST UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
Jan 29, 2026 7:05am EST Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
Dec 29, 2025 7:05am EST Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)
Nov 25, 2025 7:05am EST Unicycive Therapeutics to Participate in Upcoming Investor Events in December
Nov 12, 2025 7:05am EST Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
Nov 03, 2025 7:05am EST Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
Oct 30, 2025 7:05am EDT Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference
